High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$872K
$872,890
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
GLUE
S
Monte Rosa Therapeutics, Inc.
Dunn Edmund
• Officer • Principal Accounting Officer
Sell to Cover
2026-03-04
$2,496
|
||||||
| GLUE |
Monte Rosa Therapeutics, Inc.
|
Officer • Principal Accounting Officer
Sell to Cover
|
2026-03-04 | $2,496 | S | Form 4 |
|
GLUE
M
Monte Rosa Therapeutics, Inc.
Dunn Edmund
• Officer • Principal Accounting Officer
Other
2026-03-02
$7,188
|
||||||
| GLUE |
Monte Rosa Therapeutics, Inc.
|
Officer • Principal Accounting Officer
Other
|
2026-03-02 | $7,188 | M | Form 4 |
| GLUE |
Monte Rosa Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-03-02 | $97,974 | S | Form 4 |
|
GLUE
S
Monte Rosa Therapeutics, Inc.
Dunn Edmund
• Officer • Principal Accounting Officer
Discretionary Sell
2026-03-02
$9,380
|
||||||
| GLUE |
Monte Rosa Therapeutics, Inc.
|
Officer • Principal Accounting Officer
Discretionary Sell
|
2026-03-02 | $9,380 | S | Form 4 |
|
GLUE
S
Monte Rosa Therapeutics, Inc.
Dunn Edmund
• Officer • Principal Accounting Officer
Discretionary SellΔOwn -52.6%
2026-02-27
$455,506
|
||||||
| GLUE |
Monte Rosa Therapeutics, Inc.
|
Officer • Principal Accounting Officer
Discretionary SellΔOwn -52.6%
|
2026-02-27 | $455,506 | S | Form 4 |
|
GLUE
M
Monte Rosa Therapeutics, Inc.
Dunn Edmund
• Officer • Principal Accounting Officer
Other
2026-02-27
$337,449
|
||||||
| GLUE |
Monte Rosa Therapeutics, Inc.
|
Officer • Principal Accounting Officer
Other
|
2026-02-27 | $337,449 | M | Form 4 |
|
GLUE
S
Monte Rosa Therapeutics, Inc.
Janku Filip
• Officer • Chief Medical Officer
Discretionary SellΔOwn -12.2%
2026-02-23
$179,161
|
||||||
| GLUE |
Monte Rosa Therapeutics, Inc.
|
Officer • Chief Medical Officer
Discretionary SellΔOwn -12.2%
|
2026-02-23 | $179,161 | S | Form 4 |
| GLUE |
Monte Rosa Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-01-07 | $86,159 | S | Form 4 |
| GLUE |
Monte Rosa Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-01-07 | $7,593 | S | Form 4 |
| GLUE |
Monte Rosa Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-01-07 | $34,620 | S | Form 4 |